Patients with the CPT Hip System Femoral Stem 12/14 ... Analyst Upgrade Amid Promising Growth From New Products, Demographic ...

The highly-anticipated Z1 Femoral Hip System ... statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and ...

Zimmer Biomet had a strong 2024, bolstering its product lines and staying on top of orthopedic medtech trends.

Citi opened a “90-day positive catalyst watch” on shares of Zimmer Biomet (ZBH) while keeping a Neutral rating on the name with a $120 price ...

Medical technology company Zimmer Biomet has received approval from the U.S. Food and Drug Administration for its Oxford cementless partial knee, making it the first implant of its kind available ...

In a report released today, Matt Miksic from Barclays maintained a Sell rating on Zimmer Biomet Holdings (ZBH – Research Report), with a price ...

Zacks Research lowered their Q3 2025 earnings per share (EPS) estimates for shares of Zimmer Biomet in a research note issued on Monday, November 25th. Zacks Research analyst R. Department now expects ...

Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches ...

Zimmer Biomet's ZBH strategic product launches and stabilizing market trends bolster our confidence in this stock. Yet, factors like macroeconomic uncertainties put pressure on the bottom line.

Company's Booth Spotlights Comprehensive Hip Portfolio and Enabling Technologies ... statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including ...